CRISPR Screen Dataset
Krall EB (2017) - 4-PMID28145866
Title: KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer.
Screen Details:
- Screen Rationale : Increased drug resistance (lung cancer to trametinib (MEK inhibition))
- Screen Type : Positive Selection | Format: Pool
- Cell Line : NCI-H1299 cell | Type: Lung Cancer Cell Line (BTO)
- Throughput : High Throughput
- Enzyme : CAS9
- Phenotype : Resistance To Chemicals
- Experimental Setup : Drug Exposure | Duration: 21 Days | Condition Name: Trametinib (1.5 µM)
- Library : GECKO v2 | Type: CRISPRn | Methodology: Knockout
- Analysis Method : STARS | Number of Hits: 10 | Full Dataset Size: 20,703
- Significance : Authors have indicated that results with Score.3 (FDR) < 0.1 are to be considered significant. These results are indicated by '' in the HIT column of the table below.
Score Distribution
< 12.4993174
> 0.30107916